Globalpharma was established in 1998 and is based in Dubai Investments Park. The manufacturing facility covers an area of 27,000 sq meters and the annual capacity of the plant includes the production of 300 million tablets, 150 million capsules, and over 7 million litres of dry syrup and liquid based during an eight hour shift.
Globalpharma is currently registered in the GCC markets, ten Middle East and Asian markets, with registration underway for twelve African markets. The company was accredited by the Federal Drugs Authority in 2006-2007.
Products & Services
Globalpharma manufactures pharmaceutical products under CGMP conditions including antibiotics, cardiovascular, anti-ulcerants, analgesic, NSAIDs, food supplements, vitamins, anti-diabetics, respiratory products and anti-histamine formulations. The factory has two separate manufacturing units for penicillin products. The range of products manufactured at Globalpharma includes tablets, capsules, and dry syrups in the penicillin plant, and tablets, capsules, liquid syrups and suspensions at the general facility.
A Note On Quality Control
With quality assurance and control being given top priority, the units include extensively equipped laboratories which regularly perform chemical, instrumental analysis and microbiological testing of raw materials, finished products, and factory environment. Manufacturing and filling exercises are carried out by state-of-the-art machinery under stringent quality conditions that adhere to the norms outlined by the GCC Guidelines, US Food and Drugs Administration (F.D.A), and the UK Medicines Control Agency (MHRA).